Fluoroquinolones Need REMS With Communication Plan, AdCom Says
This article was originally published in The Pink Sheet Daily
Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.
You may also be interested in...
Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.
Advisory committee unsure how to describe fluoroquinolone-associated disability in labeling.
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.